Returning to Boston in February 2020 is the 8th Neurodegenerative Drug
Development Summit, previously World CNS. Despite the lack of clinical
trial success, new investments are being made in forward-thinking
biotechs, digital and blood-based biomarker technologies are
advancing, new targets are emerging, and gene therapy is taking the
limelight. The Neurodegenerative Drug Development Summit will unite
industry stakeholders to learn how to overcome their translational
challenges, share their progress and network for future collaborations
to accelerate the development of successful neurodegenerative
therapeutics. Don’t miss your opportunity to join over 150 fellow
CNS experts from Biogen, AbbVie, Sanofi and more, and immerse yourself
in the neurodegenerative community to help refresh the
neurodegenerative approach and challenge traditional thinking to
advance clinical progress. Speakers: Larry Brown, Executive Vice
President and Chief Scientific Officer, Noveome Biotherapeutics, Inc.,
Alison Mungenast, Principal Scientist and Neuroscience Lead, Eisai,
Amy Easton, Senior Scientific Manager, Drug Discovery, Genentech,
Aparna Vasanthakumar, Principal Research Scientist, Pharmacogenetics
and Pharmacogenomics, Genomics Research Center/Chair of PPSP,
AbbVie/ADNI, Bob Switzer, Founder, President and Chief Scientific
Officer Neuroscience, Associates, Christian Schubert, Global Head,
External Innovation, Servier, David Donabedian, Chief Executive
Officer, Axial Therapeutics, Eric Schaeffer, Senior Director,
Neuroscience Innovation, Janssen, Henrik Zetterberg, Professor,
University of Gothenburg, Ilaria Tassi, Lead Scientist, Alector, Ivana
Rubino, Global Head of Medical Alzheimer’s, Biogen, James Gorman,
Brain Targeting Program, Wyss Institute for Biologically Inspired
Engineering, Harvard, Johan Luthman, Executive Vice President and Head
of Research and Development, Lundbeck, John Renger, Chief Scientific
Officer, Cerevel Therapeutics, Jonathan Brotchie, Co-Founder, Director
and President, Atuka Inc, Krystof Bankiewicz, President and CEO, Brain
Neurotherapy Bio, Inc., Lamya Shihabuddin, Head of Genetic Neurologic
Diseases, Sanofi, Laszlo Kiss, Executive Director, WRD and Principal,
Pfizer Ventures, Leslie Shinobu, Senior Director, Clinical
Development, Biogen, Michael Gold, Vice President, Neuroscience
Development, AbbVie, Nahome Fisseha, Assistant Scientific Director,
Neuroscience Clinical Development, AbbVie, Olivier Danos, Chief
Scientific Officer, REGENXBIO, Pascal Sanchez, Director, Translational
Sciences, Denali Therapeutics, Richard Hargreaves, Vice President,
Head Neuroscience and Imaging Research and Early Development, Celgene,
Richard Ransohoff, Venture Partner, Third Rock Ventures, Ross Jeggo,
Head of Neuroscience Research, Servier, Samantha Hutten, Senior
Associate Director, Research Partnerships, Michael J Fox, Sheraz Khan,
Director of the Khan Lab, Harvard, MGH and MIT, Sid O’Bryant,
Executive Director, Institute for Translational Research; Professor,
Department of Pharmacology and Neuroscience, University of North Texas
Health Science Center, Sophie Parmentier Batteur, Director,
Neuroscience Discovery, Merck, Will Chen, Senior Director,
Translational Biology, Biogen, Yaming Wang, Senior Research Scientist,
Eli Lilly Cost: Payment required - Conference + 3 Workshops: USD
4496.0, Conference + 2 Workshops: USD 4097.0, Conference + 1 Workshop:
USD 3598.0, Conference Only: USD 2999.0 Categories: Conferences &
Tradeshows | Health & Wellness This event repeats daily until February
27, 2020: Feb 27
culture
129
Views
28/02/2020 Last update